RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (European Union), PRIME (European Union), Priority Review (China), Breakthrough Therapy (China), Orphan Drug (Japan)

Structure/Sequence

Boost your research with our ADC technology data.

view full example data

Sequence Code 452958921H

Source: *****

Sequence Code 452958931L

Source: *****

Clinical Trials associated with Risvutatug Rezetecan

JPRN-jRCT2031260631

/ Not yet recruitingPhase 3

A Phase 3, Open-label Study of Risvutatug Rezetecan versus Docetaxel in Participants with Metastatic, Chemo-naive Androgen Pathway Modulator-resistant Prostate Cancer (Previously Known as mCRPC) (EMBOLD Prostate-304)

Start Date07 Jan 2027

Sponsor / Collaborator

GlaxoSmithKline KK

NCT07892625

/ Not yet recruitingPhase 1

A Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 in Combination With ZG006 With or Without Adebrelimab in Patients With Extensive Stage Small Cell Lung Cancer

This is a multicenter, open-label Phase I study evaluating the safety, tolerability, pharmacokinetic, and efficacy of Intravenous HS-20093 in combination with ZG006 with or without adebrelimab in patients with extensive-stage small cell lung cancer.

Start Date15 Nov 2026

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

NCT07899086

/ Not yet recruitingPhase 1

A Phase I Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of HS-20093 Combination Therapy in Subjects With Advanced Non-Small Cell Lung Cancer

This is a multicenter, open-label, Phase 1 clinical study to evaluate the efficacy and safety of HS-20093 combination therapy in subjects with advanced or metastatic non-small cell lung cancer without actionable genomic alterations.

Start Date10 Nov 2026

Sponsor / Collaborator

Shanghai Hansoh Biomedical Co. Ltd.

100 Clinical Results associated with Risvutatug Rezetecan

100 Translational Medicine associated with Risvutatug Rezetecan

100 Patents (Medical) associated with Risvutatug Rezetecan

Literatures (Medical) associated with Risvutatug Rezetecan

02 Nov 2026·Cancer Discovery

Anti–B7-H3 ADCs Take Center Stage against SCLC at WCLC

Abstract::

Separate phase III trials of the anti–B7-H3 antibody–drug conjugates tambotatug pelitecan and risvutatug rezetecan significantly improved overall survival, progression-free survival, and objective response rates compared with topotecan in patients with relapsed small-cell lung cancer. In a third trial, the combination of the investigational PD-L1 x VEGF-A bispecific antibody pumitamig plus the anti–B7-H3 ADC elfetabart drozuntecan showed encouraging early efficacy in SCLC across lines of therapy and doses. The studies were presented at the 2026 World Congress on Lung Cancer in Seoul, Republic of Korea.

05 Oct 2026·MOLECULAR PHARMACEUTICS

Preclinical Evaluation of B7−H3-Targeted ADC-Based Molecular Imaging in Lung and Triple-Negative Breast Cancer

Article

Author: Wei, Yuchun ; Cai, Weibo ; Sui, Jiayu ; Engle, Jonathan W. ; Saladin, Rachel J. ; Yu, Jinming ; Qin, Jingjie ; Hu, Xudong ; Hsu, Jessica C. ; Barnhart, Todd E.

Abstract:

B7−H3 is widely expressed in multiple solid tumors but shows minimal expression in normal tissues, making it an ideal target for molecular imaging; however, its systematic investigation remains limited. In this study, we utilized the clinically investigated B7−H3-targeted antibody−drug conjugate (ADC) HS-20093 to develop and evaluate a novel immuno-positron emission tomography (immuno-PET) tracer, [89Zr]Zr-DFO-HS-20093, for accurate imaging of B7−H3 expression in lung cancer and triple-negative breast cancer models. [89Zr]Zr-DFO-HS-20093 was synthesized with high radiochemical purity (98.2 ± 0.6%). Cellular uptake assays revealed significantly higher tracer uptake in A549 cells than in 4T1 cells at 1, 2, and 4 h (all P < 0.0001), which was markedly reduced by blocking with excess unlabeled antibody. Immunofluorescence revealed predominant membrane localization of B7−H3 in 4T1 cells, whereas A549 cells exhibited pronounced intracellular distribution, suggesting enhanced internalization. In tumor-bearing mice, [89Zr]Zr-DFO-HS-20093 positron emission tomography (PET)/CT enabled clear tumor visualization, with peak uptake at 24 h post-injection in both A549 and 4T1 xenografts (9.63 ± 1.97 and 7.15 ± 3.14 μCi/mL, respectively), supporting its potential for tumor imaging. Ex vivo biodistribution data corroborated the PET findings, showing significantly higher tracer uptake in A549 tumors (5.01 ± 1.19 % ID/g) than in blocked tumors (2.89 ± 0.43 % ID/g) and 4T1 tumors (1.89 ± 0.47 % ID/g) (P = 0.034 and P = 0.003, respectively). Immunohistochemical analysis of A549 xenografts showed strong B7−H3 expression (3+), whereas 4T1 tumors exhibited lower expression levels (1−2+), further confirming that B7−H3 expression patterns were consistent with the imaging results. [89Zr]Zr-DFO-HS-20093 enables sensitive immuno-PET imaging of B7−H3 and reveals tumor-type-dependent differences in B7−H3 expression and intracellular behavior.

01 Oct 2026·ANNALS OF ONCOLOGY

Efficacy and safety of risvutatug rezetecan versus gemcitabine–docetaxel in relapsed or refractory osteosarcoma: primary results from the ARTEMIS-011 phase III trial

Article

Author: Liu, Q ; Ma, J ; Niu, X ; Li, X ; Xiao, Y ; Luo, W ; Hu, H ; Jin, Y ; Li, B ; Tang, X ; Huang, Z ; Hua, Y ; Wang, J ; Wang, H ; Yao, W ; Xie, L ; Tu, C ; Fang, M ; Zhang, X ; Chen, J ; Zhu, D

BACKGROUND:

Patients with relapsed or refractory (R/R) osteosarcoma have a poor prognosis and high unmet needs for effective therapies. In this article, we report primary results from ARTEMIS-011, the multicenter, open-label, randomized phase III trial of risvutatug rezetecan (Ris-Rez), a B7-H3-directed antibody-drug conjugate, in Chinese patients with R/R osteosarcoma after 2 or more prior lines of systemic treatment.

PATIENTS AND METHODS:

Patients (aged ≥12 years) were randomly assigned 2 : 1 to Ris-Rez 12.0 mg/kg or gemcitabine-docetaxel (GD), administered every 3 weeks, stratified by age and lung metastasis. The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR); secondary endpoints included overall survival (OS) and safety.

RESULTS:

At data cut-off (17 June 2026), 80 patients were treated with Ris-Rez and 42 with GD; median follow-up was 7.1 months. Median age was 21 years (interquartile range 17-34) with 31 (25%) adolescents (12 to <18 years). BICR-assessed PFS significantly improved with Ris-Rez compared with GD [median 5.5 compared with 1.4 months; hazard ratio (HR) 0.33, 95% confidence interval (CI) 0.20-0.55, P < 0.0001]. OS data were immature, with an HR of 0.51 (95% CI 0.21-1.23). With longer treatment duration with Ris-Rez than GD (median 4.5 compared with 1.5 months), adverse events (AEs) were reported in all patients. No treatment-related AEs (TRAEs) led to death. Grade ≥3 TRAEs occurred in 93% of patients with Ris-Rez and 83% with GD, and serious TRAEs in 64% compared with 29%, which were predominantly hematologic. TRAEs led to dose reductions in 71% of patients with Ris-Rez compared with 26% of patients with GD, and permanent discontinuation was infrequent (3.8% compared with 2.4%).

CONCLUSIONS:

In ARTEMIS-011, Ris-Rez demonstrated a statistically significant and clinically meaningful improvement in BICR-assessed PFS compared with GD, alongside a numerical trend toward improved OS and a manageable safety profile with dose modifications and supportive care, offering a promising new treatment option for patients with R/R osteosarcoma.

News (Medical) associated with Risvutatug Rezetecan

05 Nov 2026

·www.biospace.com

Summit Therapeutics Reports Financial Results and Operational Progress for the Third Quarter and Nine Months Ended September 30, 2026

Recent $2 Billion Strategic Equity Investment in Summit by AstraZeneca and Summit’s Expanding Network of Clinical Collaborations Underscore Confidence in Ivonescimab’s Potential Ivonescimab Global Clinical Development Program Continues to Grow with New Studies in Bladder and Kidney Cancers Ivonescimab Regimens Demonstrate Statistically Significant Overall Survival Benefits Versus Pembrolizumab in PD-L1–Positive Advanced NSCLC and Versus Durvalumab Plus Chemotherapy in Biliary Tract Cancer in Akeso’s Phase III Studies Conducted in China Summit Closes Third Quarter with $629.8 Million in Cash and Investments and Received $2.0 Billion from AstraZeneca in Connection with an Equity Investment Post Third Quarter MIAMI--(BUSINESS WIRE)-- $SMMT --Summit Therapeutics Inc. (NASDAQ: SMMT) today reported its financial results for the third quarter and nine months ended September 30, 2026, and provided an update on clinical and operational progress. “This quarter marked a period of meaningful momentum for Summit, highlighted by AstraZeneca’s $2 billion strategic equity investment and the expansion of our network of clinical collaborations with AstraZeneca, Daiichi Sankyo, and several others,” said Robert W. Duggan, Chairman and Co-Chief Executive Officer of Summit. “These commitments underscore ever growing confidence in ivonescimab’s potential across a broad range of solid tumors.” “Our global clinical development program for ivonescimab continues to broaden, with the announcement of ivonescimab combination collaborations with Datroway® and sone-ve, alongside new studies in bladder cancer with HARMONi-GU1, in biliary tract cancer with EA2251, and in kidney cancer with SMT112-216 and Arcus’ ARC-20 platform study,” said Dr. Maky Zanganeh, President and Co-Chief Executive Officer of Summit. “We are encouraged by the statistically significant overall survival results recently presented from Akeso’s HARMONi-2 study in PD-L1–positive advanced NSCLC and HARMONi-GI1 study in BTC, and we look forward to the upcoming initial HARMONi-3 data in first-line squamous NSCLC.” Clinical & Operational Updates Clinical and operational progress continues with ivonescimab, a novel, potentially first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule: Summit in-licensed ivonescimab from Akeso Inc. in January 2023. In total, over 5,000 patients have been treated with ivonescimab in clinical studies globally, and over 100,000 patients have been treated in the commercial setting with ivonescimab in China, as noted and updated by Akeso. Summit has exclusive rights to develop and commercialize ivonescimab in North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso retains development and commercialization rights for remaining territories, including China. Summit is currently developing ivonescimab in non-small cell lung cancer (NSCLC), colorectal cancer (CRC), urothelial carcinoma (UC), and renal cell carcinoma (RCC), specifically conducting multiregional Phase II or Phase III clinical trials in the following proposed indications or settings: HARMONi (Phase III): ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a third-generation EGFR tyrosine kinase inhibitor (TKI); HARMONi-3 (Phase III): ivonescimab combined with chemotherapy in patients with first-line metastatic NSCLC, with two distinct cohorts to be analyzed separately for squamous tumors and non-squamous tumors; HARMONi-7 (Phase III): ivonescimab monotherapy in patients with first-line metastatic NSCLC whose tumors have high PD-L1 expression; HARMONi-GI3 (Phase III): ivonescimab combined with chemotherapy in patients with first-line unresectable metastatic CRC; HARMONi-GU1 (Phase II / III): ivonescimab plus the antibody-drug conjugate (ADC) enfortumab vedotin (EV) in previously untreated patients with first-line metastatic UC; and SMT112-216 (Phase II): multiple ivonescimab-based combination treatment regimens in first line patients with metastatic clear cell RCC (ccRCC) (SMT112-216 is also referred to as AK112-216 in China). HARMONi In January 2026, the U.S. Food and Drug Administration (FDA) accepted for filing Summit's Biologics License Application (BLA) seeking approval for ivonescimab in combination with chemotherapy in patients with EGFR-mutated locally advanced or metastatic non-squamous NSCLC who have received prior EGFR TKI therapy. The BLA was submitted based on the results of the global Phase III HARMONi trial. The FDA provided a Prescription Drug User Fee Act (PDUFA) goal action date of November 14, 2026. The HARMONi study has dual primary endpoints: progression-free survival (PFS) and overall survival (OS). HARMONi met its PFS primary endpoint, becoming the first global Phase III study of an immunotherapy-based regimen to show a statistically significant PFS improvement in this setting. In the primary analysis for OS, ivonescimab in combination with chemotherapy showed a positive trend without achieving a statistically significant result. As previously disclosed, the FDA noted that a statistically significant OS benefit is necessary to support marketing authorization in this setting. Considering the safety and efficacy pro the current FDA-approved options for patients in this setting – none of which have demonstrated a statistically significant OS benefit – as well as the continued positive, regionally consistent data of this Phase III multiregional study, and discussions with key opinion leaders and physicians who have administered ivonescimab to patients, Summit believes that ivonescimab is a potential treatment option with a favorable benefit-risk profile. In September 2026, updated OS results from HARMONi were presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026). With longer follow-up, western patients replicated the survival improvement seen in Asian patients, further reinforcing the regional consistency of the efficacy results observed in the HARMONi study. The updated June 2026 analysis continued to show consistent, favorable OS results, with an OS hazard ratio of 0.76 (95% CI: 0.61 – 0.95; nominal p=0.0151) in the global intention-to-treat (ITT) population. An OS hazard ratio of 0.76 was demonstrated in the western patient subgroup (95% CI: 0.52 – 1.10), which was consistent with the ITT population and Asian subgroup. In this most recent analysis, ivonescimab continued to demonstrate an acceptable and manageable safety pro was consistent with previous Phase III data of ivonescimab plus chemotherapy. No additional safety signals were noted in this latest HARMONi data cut. These results have been made available to the FDA. HARMONi-3 Enrollment in both the squamous and non-squamous NSCLC cohorts of the global HARMONi-3 study is complete. The number of PFS events needed in the squamous cohort for the primary analysis is expected to be reached in the fourth quarter of 2026, and a planned early interim analysis for OS is expected to take place in conjunction with the primary PFS analysis. An interim analysis for OS independent of PFS is planned for the first half of 2027. For the non-squamous cohort, the number of events needed to conduct the PFS analysis is expected to be reached in the first half of 2027. HARMONi-7 Summit's global Phase III HARMONi-7 trial continues to enroll, with enrollment expected to be completed in 2027. In September 2026, interim OS data for HARMONi-2, an Akeso-sponsored Phase III study evaluating ivonescimab monotherapy in a similar setting to Summit’s HARMONi-7 trial, was presented WCLC 2026. In this protocol-specified interim analysis of OS, a secondary endpoint in the HARMONi-2 study, ivonescimab monotherapy demonstrated a statistically significant and clinically meaningful improvement compared to pembrolizumab monotherapy, achieving a hazard ratio (HR) of 0.73 (95% CI: 0.57, 0.95; p=0.009). A clinically meaningful benefit was demonstrated across important clinical subgroups, including those with PD-L1 low expression (PD-L1 Score 1-49%) and PD-L1 high expression (PD-L1 Score ≥ 50%), along with those with squamous and non-squamous histologies. In this analysis, ivonescimab continued to demonstrate an acceptable and manageable safety profile, which was consistent with previous Phase III studies of ivonescimab and no additional safety signals were noted. HARMONi-2 evaluated monotherapy ivonescimab compared to monotherapy pembrolizumab in patients with locally advanced or metastatic NSCLC whose tumors have positive PD-L1 expression. HARMONi-2 is a single region, multi-center, double-blinded Phase III study conducted in China sponsored by Akeso, with all relevant data exclusively generated, managed, and analyzed by Akeso. HARMONi-GI3 Summit is continuing to enroll the HARMONi-GI3 study, which is expected to include 900 patients. The enrollment rate has exceeded initial estimations and is currently expected to complete in Q3 2027. HARMONi-GU1 In August 2026, the company announced the planned initiation of the global, multi-regional Phase II / III HARMONi-GU1 trial expanding ivonescimab’s global registration-enabling clinical development program to now include UC, or bladder cancer. Global clinical trial site activations for and enrollment in HARMONi-GU1 have begun for the Phase II portion of this study. SMT112-216 In October 2026, Summit announced the initiation and opening of trial sites for SMT112-216, a randomized, open-label, global Phase II study of ivonescimab in previously untreated advanced ccRCC, the most common type of kidney cancer. The study, also referred to as AK112-216, is being conducted in collaboration with Summit’s partner, Akeso. Participants will be randomized to receive ivonescimab in combination with cadonilimab, ivonescimab in combination with ipilimumab, ivonescimab monotherapy, or nivolumab plus ipilimumab as an established standard-of-care comparator regimen. Cadonilimab is an investigational PD-1 x CTLA-4 bispecific antibody developed by Akeso. This study, in addition to collaborative work being performed by Arcus combining ivonescimab with the HIF2α inhibitor, casdatifan, will be used to inform registration-enabling studies in first-line ccRCC with ivonescimab. SMT112-216 has begun enrollment and plans to enroll approximately 100 patients at clinical trial sites in the U.S. and China. Additional Ivonescimab Development Updates In September 2026, Summit entered into a clinical trial collaboration with AstraZeneca to evaluate ivonescimab in combination with AstraZeneca’s Claudin 18.2-targeting ADC, sonesitatug vedotin, also referred to as sone-ve, in certain gastrointestinal cancer settings. Each company will contribute their respective compound for the combination studies to be conducted, and the parties will jointly contribute to the costs of such studies, which are intended to be sponsored by AstraZeneca. The collaboration does not include upfront payments, milestone payments, or royalty sharing provisions. Each company will retain development and commercial rights to their respective molecules. Additionally in September 2026, the company executed a non-binding Memorandum of Understanding with AstraZeneca whereby the two companies intend to enter into an agreement to conduct clinical trials combining ivonescimab with multiple AstraZeneca cancer medicines, including AstraZeneca’s leading portfolio of antibody-drug conjugates (ADCs). The companies intend to share clinical development costs of potential future studies. Each company will retain their current development and commercial rights to their respective molecules, and the agreement is mutually non-exclusive. The memorandum of understanding does not include upfront payments, milestone payments, or royalty sharing provisions. In October 2026, Summit announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with the TROP2-directed ADC datopotamab deruxtecan (Datroway®) across multiple solid tumor settings, intending to include breast and lung cancer. The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer (TNBC). The collaboration does not include upfront payments, milestone payments, or royalty sharing provisions. In October 2026, HARMONi-GI1, an Akeso-sponsored Phase III study evaluating ivonescimab plus chemotherapy in patients with BTC, was presented as part of the Presidential Symposium at the 2026 European Society for Medical Oncology Annual Congress (ESMO 2026). Ivonescimab in combination with chemotherapy demonstrated a statistically significant improvement in OS when compared to durvalumab in combination with chemotherapy, with a hazard ratio of 0.75 (95% CI: 0.61, 0.92; p=0.0031). In the HARMONi-GI1 study, ivonescimab plus chemotherapy demonstrated an acceptable and manageable safety pro was consistent with previous Phase III studies of ivonescimab plus chemotherapy. No additional safety signals were identified. Summit plans to continue further expansion of the global clinical development program for ivonescimab, including additional Phase III studies, in additional settings and tumor types. The company will continue to provide more details in the coming months with respect to additional Phase III studies evaluating ivonescimab beyond NSCLC, CRC, UC, RCC, BTC, and head and neck squamous cell carcinoma (HNSCC). In addition to the multiregional studies conducted and sponsored by Summit, Akeso is enrolling several single-region Phase III studies exclusively in China in multiple indications outside of NSCLC, including BTC, TNBC, HNSCC, small cell lung cancer, CRC, and pancreatic cancer. Summit’s clinical trial collaborations continue to progress as planned. In the second quarter of 2025, the company announced a clinical collaboration with Revolution Medicines, Inc. (RevMed) to evaluate ivonescimab in combination with three RAS(ON) inhibitors, including the multi-selective inhibitor daraxonrasib (RMC-6236), G12D-selective inhibitor zoldonrasib (RMC-9805), and G12C-selective inhibitor elironrasib (RMC-6291), in solid tumor settings with RAS mutations. As previously announced, the initial study under this collaboration, sponsored by RevMed, began enrolling patients in the first quarter of 2026. In the first quarter of 2026, Summit announced a clinical collaboration with GORTEC, a European Head and Neck Oncology and Radiotherapy Group based in France, to evaluate ivonescimab monotherapy and ivonescimab in combination with ligufalimab, Akeso’s proprietary anti-CD47 monoclonal antibody, against monotherapy pembrolizumab in a randomized three-arm study. The Phase III study, GORTEC 2024-04 ILLUMINE (NCT07264075), is sponsored by GORTEC and is intended to be conducted in multiple countries in Europe and in China; Summit may consider the expansion of this study into the United States. ILLUMINE began enrolling patients in the second quarter of 2026. In the first quarter of 2026, the company announced a clinical collaboration with GSK plc to evaluate ivonescimab in combination with GSK’s novel B7-H3 ADC, risvutatug rezetecan, in multiple solid tumors. The initial study under this collaboration agreement is currently enrolling. In July 2026, Summit announced a clinical collaboration with Arcus Biosciences, Inc. to evaluate ivonescimab in combination with Arcus’ novel HIF-2α inhibitor, casdatifan, in ccRCC. Initial data from the study under this collaboration agreement is expected to be generated by mid-2027. In September 2026, as noted above, Summit announced a clinical collaboration with AstraZeneca to evaluate ivonescimab in combination with sone-ve in certain gastrointestinal cancer settings. In October 2026, as noted above, Summit announced a clinical trial collaboration with AstraZeneca and Daiichi Sankyo to evaluate ivonescimab in combination with Datroway® across multiple solid tumor settings, intended to include breast and lung cancer. The companies intend to begin with a Phase III trial in first-line TNBC. In October, 2026, Summit announced a clinical collaboration with ECOG-ACRIN Cancer Research Group to evaluate ivonescimab in combination with chemotherapy compared to pembrolizumab or durvalumab in combination with chemotherapy in advanced biliary tract cancer (BTC) in a registration-enabling Phase II / III clinical study, EA2251. The primary endpoint for the study is OS and activation of U.S. clinical trial sites is expected to begin in the fourth quarter of 2026. Clinical trial collaborations and investigator sponsored trials (ISTs) with leading academic organizations, including MD Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, and Dana Farber Cancer Institute, among others, continue to progress and expand evaluating ivonescimab in solid tumors. Summit has agreed to support more than 65 ISTs, of which 26 have started and are actively enrolling. Financial Highlights On October 5, 2026, AstraZeneca completed a $2.0 billion strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approximately 108,955 shares of preferred stock convertible into shares of common stock of Summit at a 1:1,000 ratio. The investment by AstraZeneca totaled $2.0 billion. At the conversion ratio, the investment represents a common stock price equal to $18.36, representing a premium over the closing trading price on the day the investment was announced. For additional details on the financial terms, please refer to the Summit press release issued on September 28, 2026. Third quarter 2026 financial highlights are as follows: Cash and Cash Equivalents and Short-term Investments Aggregate cash and cash equivalents and short-term investments were $629.8 million and $713.4 million at September 30, 2026 and December 31, 2025, respectively. During the third quarter of 2026, the company raised $94.1 million in gross proceeds through its ATM facility. GAAP and Non-GAAP Operating Expenses GAAP operating expenses were $214.6 million for the third quarter of 2026, compared to $234.2 million for the same period of the prior year. The decrease in GAAP operating expenses was due to the decrease in stock-based compensation expense of $83.1 million primarily related to the modification to the company's performance-based stock option awards during the second quarter of 2025, offset by an increase primarily in R&D expenses driven by the expansion of clinical studies and development costs related to ivonescimab. Non-GAAP operating expenses were $166.9 million for the third quarter of 2026, compared to $103.4 million for the same period of the prior year. The increase in Non-GAAP operating expenses was primarily driven by the expansion of clinical studies and development costs related to ivonescimab. GAAP and Non-GAAP Research and Development (R&D) Expenses GAAP R&D expenses were $169.1 million for the third quarter of 2026, compared to $131.1 million for the same period of the prior year. The increase was driven by the expansion of clinical studies and development costs related to ivonescimab, offset by the decrease in stock-based compensation expense of $16.7 million primarily related to the modification to the company's performance-based stock option awards during the second quarter of 2025. Non-GAAP R&D expenses were $145.2 million for the third quarter of 2026, compared to $90.5 million for the same period of the prior year. The increase was primarily driven by the expansion of clinical studies and development costs related to ivonescimab. GAAP and Non-GAAP General and Administrative (G&A) Expenses GAAP G&A expenses were $45.5 million for the third quarter of 2026, compared to $103.1 million for the same period of the prior year. The decrease was due to the decrease in stock-based compensation expense of $66.4 million primarily related to the modification to the company's performance-based stock option awards during the second quarter of 2025. Non-GAAP G&A expenses were $21.7 million for the third quarter of 2026, compared to $12.9 million for the same period of the prior year. The increase was primarily driven by the expansion of infrastructure and our headcount to support the development of ivonescimab. GAAP and Non-GAAP Net Loss GAAP net loss in the third quarter of 2026 and 2025 was $208.4 million or $(0.26) per basic and diluted share, and $231.8 million or $(0.31) per basic and diluted share, respectively. Non-GAAP net loss in the third quarter of 2026 and 2025 was $160.7 million or $(0.20) per basic and diluted share, and $101.0 million or $(0.13) per basic and diluted share, respectively. Summit Therapeutics Update Conference Call Given the FDA's November 14 PDUFA goal action date for the pending BLA, Summit plans to host a conference call and webcast following the FDA's action. Following the FDA’s action and prior to the call, Summit will issue a press release with the conference call details, including dial-in information, which will also be posted on the Investor Relations section of Summit's website, Slides will be displayed during the live webcast, and all interested parties are encouraged to listen in. An archived replay will be available on the website shortly after the call. About Ivonescimab Ivonescimab, known as SMT112 in Summit’s license territories, North America, South America, Europe, the Middle East, Africa, and Japan, and as AK112 outside of Summit’s license territories, is a novel, potential first-in-class investigational bispecific antibody combining the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects associated with blocking VEGF into a single molecule. By design, ivonescimab displays unique cooperative binding to each of its intended targets with multifold higher affinity to PD-1 when in the presence of VEGF. This design is intended to differentiate ivonescimab as there is potentially higher expression (presence) of both PD-1 and VEGF in tumor tissue and the tumor microenvironment (TME) as compared to normal tissue in the body. Summit believes ivonescimab’s specifically engineered tetravalent structure (four binding sites) enables higher avidity (accumulated strength of multiple binding interactions) in the TME (Zhong, et al , iScience, 2025). This tetravalent structure, the intentional novel design of the molecule, and bringing these two targets into a single bispecific antibody with cooperative binding qualities have the potential to direct ivonescimab to the tumor tissue versus healthy tissue. The intent of this design, together with a half-life of 6 to 7 days after the first dose (Zhong, et al, iScience, 2025) increasing to approximately 10 days at steady state dosing, is to improve upon previously established efficacy thresholds, side effects, and safety profiles associated with prior approved drugs to these targets. Contacts Contact Summit Investor Relations: Nathan LiaBraaten Senior Director, Investor Relations Tracy Jones Director, Media & Public Relations investors@smmttx.com media@smmttx.com Read full story here

Phase 3Phase 2Clinical ResultLicense out/in

27 Oct 2026

·www.hspharm.com

2026 ESMO | HANSOH PHARMA ANNOUNCES POSITIVE PRIMARY RESULTS FROM PHASE 3 ARTEMIS-011 STUDY OF RISVUTATUG REZETECAN (HS-20093) IN PATIENTS WITH RELAPSED OR REFRACTORY OSTEOSARCOMA

Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise headquartered in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (“CNS”) and anti-infectives. Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as oncology, metabolism, immunology, central nervous system (“CNS”) and anti-infectives. After more than 20 years of continuous investment in R&D, Hansoh Pharma has marketed 7 innovative drugs and has over 30 innovative drug programs in different clinical stages with over 50 clinical trials in progress, forming a rich pipeline. Find the latest and most complete information about Hansoh Pharma! Hansoh Pharma, a leading innovation-driven pharmaceutical company in the PRC, is committed to improving human health through unremitting innovation, focusing mainly on such areas as anti-tumor, anti-infectives, CNS diseases, metabolic diseases, autoimmune diseases. Hansoh Pharma has always focused on corporate governance, corporate behavior, product safety and quality, access to healthcare, human resource development, environmental protection and community enhancement as the focus and the basis of ESG management, and has been continually committed to improving the medicine availability and the innovative development in fields with unmet clinical needs. We welcome talents worldwide to join us with their entrepreneurship and achieve new levels of success in their career! Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Release Date：2026/10/27 Font Size    - Risvutatug Rezetecan (HS-20093), administered at 12.0 mg/kg once every three weeks, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in heavily pretreated patients with relapsed or refractory (R/R) osteosarcoma. SHANGHAI, October 27, 2026 — Hansoh Pharmaceutical Group Co., Ltd. (Hansoh Pharma, 03692.HK) announced that the primary results from the Phase 3 ARTEMIS-011 study of risvutatug rezetecan (“Ris-Rez”) (HS-20093/GSK5764227) were presented orally as a Late-Breaking Abstract (LBA) at the Presidential Symposium of the 2026 European Society for Medical Oncology (ESMO) Congress, held in Madrid, Spain, from October 23 to 27. The study evaluated Ris-Rez versus gemcitabine plus docetaxel (GD) in heavily pretreated patients with R/R osteosarcoma following failure of at least two prior lines of therapy. At the prespecified analysis, the study met its primary endpoint of PFS as assessed by blinded independent central review (BICR), demonstrating a statistically significant and clinically meaningful improvement, with a 67% reduction in the risk of disease progression or death. Ris-Rez is a proprietary B7-H3—directed antibody-drug conjugate (ADC) independently developed by Hansoh Pharma. It consists of a fully human anti-B7-H3 IgG1 monoclonal antibody conjugated to a topoisomerase I inhibitor (TOP1i) payload (rezetecan) through a cleavable linker. In China, Ris-Rez is currently being evaluated in pivotal Phase 3 studies in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), osteosarcoma and oesophageal cancer. On September 24, 2026, the National Medical Products Administration (NMPA) of China accepted the Biologics License Application (No. CXSS2600155) for Ris-Rez in the treatment of osteosarcoma and granted it Priority Review status. To date, Ris-Rez has received 12 regulatory designations, including Breakthrough Therapy Designation and Orphan Drug Designation, across China, the United States, Japan and Europe. Primary results from ARTEMIS-011 presented at ESMO 2026 showed that Ris-Rez significantly improved PFS in patients with R/R osteosarcoma compared with GD -- an improvement that was both statistically significant and clinically meaningful. This is the first positive Phase 3 study in R/R osteosarcoma in nearly 30 years. Ris-Rez is also the first and only B7-H3—directed ADC to demonstrate a statistically significant benefit across multiple tumour types. With positive Phase 3 results now achieved, Ris-Rez has reached a key milestone in the clinical development of B7-H3—directed ADCs, advancing from clinical study towards two regulatory submissions in China. Hansoh Pharma is continuing to advance the development of Ris-Rez across multiple tumour types and treatment lines, fully exploring the therapeutic potential of the B7-H3 ADC and bringing China’s innovations to benefit more patients. GSK holds exclusive rights to develop and commercialise Ris-Rez outside mainland China, Hong Kong, Macau and Taiwan, and is advancing a broad global clinical development programme across lung cancer, prostate cancer and other solid tumours. LBA Presentation Details: Presentation Title: Risvutatug Rezetecan Versus Gemcitabine and Docetaxel in Heavily Pretreated Patients With Relapsed or Refractory Osteosarcoma: Primary Results From the Phase 3 ARTEMIS-011 Study Session: Presidential Symposium III Abstract No.: LBA9 Date/Time: Monday, October 26, 2026, 16:30–16:42 CET / UTC +1 Presenter: Prof. Lu Xie, Peking University People's Hospital About the ARTEMIS-011 Study ARTEMIS-011 is a multi-centre, open-label, randomised (2:1), controlled Phase 3 study in which 122 patients with R/R osteosarcoma after failure of at least two prior lines of therapy were randomised to receive risvutatug rezetecan (12.0 mg/kg IV once every three weeks) or gemcitabine plus docetaxel, with as of the data cutoff date of June 17, 2026 (median follow-up: 7.1 months). Efficacy Progression-free survival (BICR, primary endpoint): Median PFS was 5.5 months with Ris-Rez vs 1.4 months with gemcitabine plus docetaxel (HR=0.33; 95% CI: 0.20-0.55; p<0.0001), a 67% reduction in the risk of disease progression or death. Investigator-assessed PFS also showed a consistent benefit vs GD: median PFS was 5.6 months with Ris-Rez vs 1.0 months with GD (HR=0.30; 95% CI: 0.19-0.50; p<0.0001). Benefit was consistent across all prespecified subgroups, including age, sex, lung metastasis, baseline tumour burden, ECOG PS, and number of prior lines of therapy. Response (BICR): ORR was 15% vs 2% and DCR was 76% vs 33%; median duration of response was 7.6 months with Ris-Rez. Investigator-assessed ORR, DCR and DOR were consistent with BICR-assessed results. Overall survival: OS data were immature but suggested a numerical trend toward an OS benefit with Ris-Rez (median not reached in either arm; HR=0.51; 95% CI: 0.21-1.23). Safety Ris-Rez showed a manageable safety profile in this heavily pretreated population. The most common treatment-related adverse events (TRAEs) of any grade and of Grade ≥ 3 in both arms were haematological; no Grade 5 (fatal) event occurred in either arm. Grade ≥ 3 TRAEs occurred in 93% of patients with Ris-Rez and 83% with GD, and serious TRAEs in 64% versus 29%, which were predominantly haematologic. Treatment-related interstitial lung disease (ILD) was observed in only 1 patient (Grade 2) in the Ris-Rez arm, and it resolved with supportive management. Longer treatment duration was observed with Ris-Rez (median 4.5 vs 1.5 months). These results suggest that Ris-Rez represents a promising potential treatment option for patients with previously-treated R/R osteosarcoma About Osteosarcoma Osteosarcoma is the most common malignant bone tumour, accounting for 35% of all malignant bone tumours, and has been included in the Second Batch of Rare Disease Catalogue issued by the National Health Commission of China [1]. The median age at onset of osteosarcoma is 20 years, and it is the most common primary malignant bone tumour in children and adolescents. Approximately 20%-30% of patients with localised (non-metastatic) osteosarcoma and 80% of patients with metastatic osteosarcoma will progress to an advanced stage (relapse or metastasis), whereas the 5-year survival rate of patients with advanced osteosarcoma is only about 20% [2,3]. Globally, patients with relapsed or refractory osteosarcoma after first-line chemotherapy have limited treatment options and lack a clear standard of care [4,5]. For patients whose osteosarcoma progresses after two or more prior lines therapy, treatment options are even more limited, representing a substantial unmet clinical need. References [1] National Health Commission of the People's Republic of China. Second Batch of Rare Disease Catalogue, Document No. 26 (2023), September 18, 2023. [2] Durfee RA, Mohammed M, Luu HH. Review of Osteosarcoma and Current Management. Rheumatol Ther. 2016 Dec;3(2):221-243. [3] Meltzer PS, Helman LJ. New Horizons in the Treatment of Osteosarcoma. N Engl J Med. 2021;385(22):2066-2076. [4] National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Bone Cancer. July 21, 2026. Version 1.2027. [5] Chinese Society of Clinical Oncology (CSCO). CSCO Clinical Practice Guidelines: Bone and Soft Tissue Cancer (2025). About Hansoh Pharma Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK). Statements 1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional. Forward-Looking Statements This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK). - Risvutatug Rezetecan (HS-20093), administered at 12.0 mg/kg once every three weeks, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) in heavily pretreated patients with relapsed or refractory (R/R) osteosarcoma. About Hansoh Pharma Hansoh Pharma is a leading innovation-driven pharmaceutical enterprise in China. With the mission of "continuous innovation for better life", the company focuses on major disease therapeutic areas such as oncology, metabolism, immunology, central nervous system (CNS) and anti-infectives. Hansoh Pharma has launched 7 innovative medicines that generate product sales in China, with the revenue from innovative medicines and collaborative products exceeding 80%, forming a rich product pipeline. The company has consistently ranked among the top 100 global pharmaceutical companies and is recognized as one of the top 3 pharmaceutical R&D enterprises in China, and is designated as a National Key High-Tech Enterprise and a National Technology Innovation Demonstration Enterprise. Hansoh Pharma was listed on the Hong Kong Stock Exchange in June 2019 (stock code: 03692.HK). Statements 1. This announcement is intended for healthcare professionals only and not for advertising purposes.2. Hansoh Pharma does not recommend the use of any unapproved drugs or off-label indications, nor does it make recommendations regarding any drug or indication.3. The information provided in this announcement is for reference only; please follow the advice or guidance of a physician or other healthcare professional. Any treatment-related decisions made by healthcare professionals should be based on the specific circumstances of the patient and should be used in accordance with the instructions for the drug.4. For more detailed information about any company products, medical treatments, or diseases, please consult a healthcare professional. Forward-Looking Statements This press release is intended to provide information about Hansoh Pharmaceutical Group Co., Ltd. and its affiliates, including their subsidiaries (collectively referred to as "Hansoh Pharma"). It does not constitute a disclosure of information about Hansoh Pharma or any investment recommendations.The information contained in this release may include forward-looking statements related to Hansoh Pharma's business and product prospects, as well as its plans, beliefs, expectations, and strategies. These statements are predictions based on speculative assumptions and are not guarantees of future performance. They are subject to risks and uncertainties, such as scientific, commercial, political, economic, financial, legal factors as well as competitive environment and social conditions, many of which are beyond Hansoh Pharma's control and difficult to predict, thus actual results may differ significantly from what is stated here, and past securities price trends should not be used as a guide for future market conditions. As such, investors should exercise caution when using this information to make investment decisions. Phrases such as "commit," "expect," "believe," "predict," "anticipate," "forecast," "intent,"“project,” “may,” “will,” “should,” “plan,” “could,” “continue,” “target,” “contemplate,” “estimate,” “guidance,” “possible,” “potential,” “pursue,”“likely,”and words and terms of similar terms substance used in connection with any discussion of future plans, actions or events indicate forward-looking statements.Hansoh Pharma does not commit to or guarantee the accuracy, timeliness, or completeness of forward-looking information and assumes no obligation to update or revise these forward-looking statements. Neither Hansoh Pharma nor any of its directors, employees, or agents will be responsible for any forward-looking statements that prove to be inaccurate or unachievable and any losses or damages incurred by users due to reliance on the information provided herein, including but not limited to direct, incidental, indirect, or punitive damages.All information in this press release is current as of the date of release. Hansoh Pharma assumes no responsibility to update or revise this information in light of new developments, future events, or other circumstances, except as required by law. Additionally, Hansoh Pharma reserves the right to make changes, corrections, or discontinuations to all or part of the content of this press release at any time without notice. For information specifically related to the listed company, investors are encouraged to refer to the announcements and financial reports of Hansoh Pharma (03692.HK). If you would like to report any adverse event involving Hansoh's products, please contact us by: Tel：+86-400-828-5227or+86-518-83096666 E-mail：PV.SERVICE@hspharm.com

Clinical ResultPhase 3Breakthrough TherapyPriority ReviewNDA

26 Oct 2026

·firstwordpharma.com

ESMO26: GSK, Hansoh's Ris-Rez nearly quadruples PFS in bone cancer

GSK said Monday that a B7-H3-targeting antibody-drug conjugate (ADC) it is co-developing with Hansoh Pharmaceutical reduced the risk of disease progression or death by 67% versus chemotherapy in a Phase III trial involving patients with a rare bone cancer.The open-label ARTEMIS-011 study included 122 patients in China aged 12 and older whose osteosarcoma had progressed or relapsed after at least two prior lines of systemic therapy. Participants received either risvutatug rezetecan (Ris-Rez) or a combination of gemcitabine and docetaxel.The trial, conducted by Hansoh, was toplined in July, shortly after an earlier clinical win in advanced or relapsed small-cell lung cancer (SCLC)Detailed results from ARTEMIS-011, presented Monday at the European Society for Medical Oncology (ESMO) congress, showed that after a median follow-up of 7.1 months, the primary endpoint of progression-free survival was 5.5 months with Ris-Rez versus 1.4 months with chemotherapy.Although overall survival data remain immature, researchers reported a "favourable trend" for Ris-Rez, with a hazard ratio of 0.51, according to the study abstract."The magnitude of effect is substantial," Eric Richards, who heads oncology product development at GSK, told Reuters. "It gives us a ⁠lot of confidence that what we're hoping for — activity across these different tumours — is likely to come to fruition."However, the efficacy benefit came alongside a higher rates of toxicity, with grade ≥3 treatment-related adverse events (TRAEs) reported in 93% of patients receiving Ris-Rez, compared to 83% for chemotherapy; in both arms, most were haematologic events. TRAEs leading to discontinuation occurred in 4% and 2% of patients, respectively.GSK noted that Ris-Rez was administered at 12 mg/kg in ARTEMIS-011, compared to a dose of 8 mg/kg in the earlier SCLC trial, ARTEMIS-008, with the higher dose selected "to account for potential difficulty in penetrating bone tissue."GSK licensed ex-China rights to Ris-Rez (formerly HS-20093) from Hansoh in 2023, alongside the B7-H4–targeting ADC mocertatug rezetecan (HS-20089), through separate deals worth up to $1.7 billion and $1.6 billion, respectively.GSK began the Phase Ib/II EMBOLD Sarcoma-202 trial of Ris-Rez earlier this year in previously treated unresectable advanced or metastatic sarcomas, including osteosarcoma.

ADCClinical ResultPhase 3

100 Deals associated with Risvutatug Rezetecan

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Osteosarcoma	NDA/BLA	China	Changzhou Hansoh Pharmaceutical Co., Ltd.	24 Sep 2026
Small Cell Lung Cancer	NDA/BLA	China	Changzhou Hansoh Pharmaceutical Co., Ltd.	02 Sep 2026
Small Cell Lung Cancer	NDA/BLA	China	Jiangsu Hansoh Pharmaceutical Group Co., Ltd.	02 Sep 2026
Bone Diseases	Phase 3	-	GlaxoSmithKline KK	07 Jan 2027
Adenocarcinoma of prostate	Phase 3	United States	GlaxoSmithKline KK	22 Sep 2026
Adenocarcinoma of prostate	Phase 3	Japan	GlaxoSmithKline KK	22 Sep 2026
Adenocarcinoma of prostate	Phase 3	Argentina	GlaxoSmithKline KK	22 Sep 2026
Adenocarcinoma of prostate	Phase 3	Australia	GlaxoSmithKline KK	22 Sep 2026
Adenocarcinoma of prostate	Phase 3	Brazil	GlaxoSmithKline KK	22 Sep 2026
Adenocarcinoma of prostate	Phase 3	Canada	GlaxoSmithKline KK	22 Sep 2026

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT06551142 (ESMO2026)	Phase 1/2	Advanced Malignant Solid Neoplasm	301	Risvutatug rezetecan (Ris-Rez)	wdpkygsgta(ymfptuurki) = zwrbaatfvh kbxfsdjzon (hqrmqqotaj ) View more	Positive	23 Oct 2026
NCT06551142 (EMBOLD PanTumor-101, ESMO2026)	Phase 1	Extensive stage Small Cell Lung Cancer	50	Risvutatug rezetecan (Ris-Rez) 6 mg/kg Q3W	bkdymdklhz(wrewrjmkkr) = mhemjqxiwk sicdkognew (ugvruwvslm ) View more	Positive	23 Oct 2026
				Risvutatug rezetecan (Ris-Rez) 8 mg/kg Q3W	bkdymdklhz(wrewrjmkkr) = lublvohyxr sicdkognew (ugvruwvslm ) View more
NCT06498479 (ARTEMIS-008, WCLC2026)	Phase 3	Recurrent Lung Small Cell Carcinoma	461	Risvutatug Rezetecan 8.0 mg/kg Q3W	khyhaajzoz(qiviiojngh) = zyuoplowkk csdxcpdyjf (sxeguakwvk ) View more	Positive	12 Sep 2026
				Topotecan 1.2 mg/m2 Q3W	khyhaajzoz(qiviiojngh) = baeepddxxa csdxcpdyjf (sxeguakwvk ) View more
NCT05276609 (ARTEMIS-001, Pubmed \| Cancer Cell \| NEWS) Manual	Phase 1	Lung Cancer	306	HS-20093 (ES-SCLC)	ogibnadehl(gmkdjryojk) = included decreased neutrophil (25.5% vs. 50.5%) and white blood cell counts (19.7% vs. 42.4%), and anemia (16.8% vs. 34.3%), respectively. wikbkrykrr (hbroncdlse ) View more	Positive	05 Mar 2026
				HS-20093 (NSCLC)
NCT06001255 (ASCO_GU2026) Manual	Phase 2	Metastatic castration-resistant prostate cancer	50	HS-20093	uusgpmmwss(maxeldvzqa) = wgfvcqxeok gdndfkmmym (qwenkfneae, 18.0 - 51.8) View more	Positive	23 Feb 2026
				HS-20093 (Taxane-naïve in mCRPC setting)	uusgpmmwss(maxeldvzqa) = jyuxrhhtek gdndfkmmym (qwenkfneae, 9.1 - 61.4) View more
NCT05830123 (ARTEMIS-002, ESMO2025) Manual	Phase 2	Sarcoma	68	HS-20093 8.0 mg/kg (Osteosarcoma)	zyxisfmqom(xweewyzdem) = xktuzoacsh icejequpkf (gpfmtfpwjq ) View more	Positive	19 Oct 2025
				HS-20093 12.0 mg/kg (Osteosarcoma)	zyxisfmqom(xweewyzdem) = zmcnkrjqkj icejequpkf (gpfmtfpwjq ) View more
NCT05276609 \| NCT05830123 \| NCT06112704 \| NCT06007729 \| NCT06001255 (HS-20093, AACR2025)	Phase 1/2	Advanced Malignant Solid Neoplasm	508	HS-20093 8.0 mg/kg	xkvuldgwtg(ymbwcadaol) = neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased and anaemia kotjdzuqdj (zgzwlnqxkb ) View more	Positive	29 Apr 2025
				HS-20093 10.0 mg/kg
NCT05276609 (ARTEMIS-001, WCLC2024) Manual	Phase 1	Extensive stage Small Cell Lung Cancer	56	HS-20093 8.0 mg/kg	aptvculnaz(qoyzepamkg) = zbrvxwufvn rknjledckh (brpglahcno ) View more	Positive	08 Sep 2024
				HS-20093 10.0 mg/kg	aptvculnaz(qoyzepamkg) = akzvcnvnbl rknjledckh (brpglahcno ) View more
NCT05276609 (ARTEMIS-001, ASCO2024) Manual	Phase 1	Small Cell Lung Cancer	56	HS-20093HS-20093 8.0 mg/kg	oioqotgojd(kdtlwsjobk) = zuritvrtdb kuuzaerxcb (phoiryblys ) View more	Positive	24 May 2024
				HS-20093HS-20093 10.0 mg/kg	oioqotgojd(kdtlwsjobk) = qnjbgwwrvg kuuzaerxcb (phoiryblys ) View more
NCT05830123 (ARTEMIS-002, ASCO2024) Manual	Phase 2	Osteosarcoma, Recurrent Last line	34	HS-20093 12 mg/kg	jgukhboufd(oedwkhysha) = nlpagehiid szhcozgujd (dbbvuiknfe ) View more	Positive	24 May 2024
				HS-20093 (8.0 mg/kg)	wuzjduvzdj(kxwxsoqekg) = ymlamuwhuo valqjuspno (khkznymswm )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis